Related references
Note: Only part of the references are listed.Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis
Thomas Baumruker et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
FTY720: Placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects
Robert Schmouder et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Molecular and cellular diversity of neuronal G-protein-gated potassium channels
L Koyrakh et al.
JOURNAL OF NEUROSCIENCE (2005)
Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3
M Tölle et al.
CIRCULATION RESEARCH (2005)
FTY720 pharmacokinetics in mild to moderate hepatic impairment
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects
JM Kovarik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Signaling and biological actions of sphingosine 1-phosphate
T Hla
PHARMACOLOGICAL RESEARCH (2003)
FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity
V Brinkmann et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Share Paper
